Spironolactone
| Spironolactone | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 416.60 g/mol [1] |
| Appearance | Crystals from methanol [1] |
| Odor | Mild mercaptan-like odor [1] |
| Melting point | 198-207 [1] |
| Boiling point | 134 °C [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of sulfoxides. [1] |
| Solubility | Soluble in most organic solvents [1] |
| Predicted LogP | 2.9 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C24H32O4S |
| IUPAC name | S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| SMILES | CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C |
| InChI | InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 |
| InChIKey | LXMSZDCAJNLERA-ZHYRCANASA-N |
| CAS number | 52-01-7 |
| UNII | 27O7W4T232 |
| PubChem CID | 5833 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | Spironolactone: 1.4 hours, 7α-thiomethylspironolactone: 13.8 hours, 6β-hydroxy-7α-thiomethylspironolactone: 15.0 hours, Canrenone: 16.5 hours |
| Metabolism | Liver, others:, • Deacetylation via carboxylesterase, • S-Oxygenation via flavin-containing monooxygenase, • S-Methylation via thiol S-methyltransferase, • Dethioacetylation, • Hydroxylation via CYP3A4, • Lactone hydrolysis via PON3 |
| Excretion | Urine, bile |
| Routes of administration | By mouth, topical |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - ip: 260 mg/kg Rabbit: - ip: 866 mg/kg Rat: - ip: 277 mg/kg [1] |
Spironolactone (also known as Aldactone, Verospirone, Spirolactone, Spiresis, Uractone, Xenalon, spironolattone, Espironolactona, Spironolactonum or Abbolactone) is a antiandrogen, antimineralocorticoid and prodrug substance of the steroid class.
Chemistry
Stereochemistry []
Spironolactone is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Spironolactone matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- diuretics (C03)
- aldosterone antagonists and other potassium-sparing agents (C03D)
- aldosterone antagonists (C03DA)
- (C03DA01)
- spironolactone (C03DA01)
MeSH Classification
Mechanism of action []
Aldosterone is a key hormone in the renin-angiotensin-aldosterone system. By binding to the mineralocorticoid receptor at the distal tubules and collecting duct, it causes sodium reabsorption and potassium secretion, increases vascular stiffness and remodelling, and activates pro-inflammatory pathways. Spironolactone and its active metabolites are aldosterone antagonists that produce a potassium-sparing diuretic effect. They competitively bind to receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents that act more proximally in the renal tubule. [1]
Metabolism
Spironolactone acts as a prodrug for:
| Metabolic pathways [] |
|---|
Interactions []
Medical side effects []
51 side effects listed on drug labels in SIDER 4.1 (spironolactone).
- Agranulocytosis
- Alopecia
- Amenorrhoea
- Anaphylactic shock
- Ataxia
- Confusional state
- Feeling abnormal
- Malaise
- Drug eruption
- Diarrhoea
- Dizziness
- Somnolence
- Eosinophilia
- Toxic epidermal necrolysis
- Dermatitis
- Rash
- Body temperature increased
- Drug fever
- Gastritis
- Gynaecomastia
- Headache
- Hyperkalaemia
- Hypersensitivity
- Hypertrichosis
- Renal failure acute
- Muscle spasms
- Cramp muscle
- Lethargy
- Leukopenia
- Breast pain
- Nausea
- Pruritus
- Renal failure
- Erythema multiforme
- Stevens-Johnson syndrome
- Thrombocytopenia
- Ulcer
- Urticaria
- Vasculitis
- Vomiting
- Menstruation irregular
- Discomfort
- Ill-defined disorder
- Rash erythematous
- Gastric haemorrhage
- Semen analysis abnormal
- Erectile dysfunction
- Benign breast neoplasm
- Gastrointestinal disorder
- Breast cancer
- Breast enlargement
Indications
- Adenoma benign
- Alkalosis hypokalaemic
- Angina pectoris
- Ascites
- Benign essential hypertension
- Cardiac failure
- Cardiac failure congestive
- Coma hepatic
- Diabetes mellitus
- Diabetic nephropathy
- Digitalis intoxication (NOS)
- Discomfort
- Diuresis
- Essential hypertension
- Gravitational oedema
- Hepatic cirrhosis
- Hirsutism
- Hyperaldosteronism
- Hyperlipidaemia
- Hypernatraemia
- Hyperplasia adrenal
- Hypertension
- Hypokalaemia
- Hypotension
- Hypotensive
- Hypovolaemia
- Idiopathic edema
- Malignant hypertension
- Myocardial infarction
- Nephrotic syndrome
- Oedema
- Pre-eclampsia
- Pregnancy
- Primary hyperaldosteronism
- Secondary aldosteronism
Subjective effects []
| alina / Spironolactone [] | |
|---|---|
Routes:
| |
| emily / Spironolactone [] | |
|---|---|
Routes:
| |
| Pilz / Spironolactone [] | |
|---|---|
Routes:
| |
| x86pup / Spironolactone [] | |
|---|---|
Routes:
| |
Legal status []
External links []
- Spironolactone (Wikipedia)
- Spironolactone (PubChem)
- Spironolactone (Wikidata)
- Spironolactone (DrugBank)
- Spironolactone (ChEMBL)
- Spironolactone (ChEBI)
- Spironolactone (Common Chemistry)
- Spironolactone (HMDB)
- Spironolactone (KEGG)
- Spironolactone (EPA DSSTox)
- Spironolactone (Effect Index)
- Spironolactone (UNII)
- Spironolactone (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5833, Spironolactone. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5833
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Spironolactone. UNII: 27O7W4T232. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/27O7W4T232
Aldactone 25 mg Film-Coated TabletsSummary of Product Characteristics (SmPC). (emc). 3 February 2022. https://www.medicines.org.uk/emc/product/1619/smpc
Qaialdo EPAR. European Medicines Agency (EMA). 25 July 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo
Qaialdo. Union Register of medicinal products. 31 May 2023. https://ec.europa.eu/health/documents/community-register/html/h1731.htm
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:01:34 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 19:01:30 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 19:01:30 |
| gsrs | ok | 2026-11-20 19:01:30 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014565) | 2026-11-20 19:01:30 |
| kegg | ok | 2026-11-20 19:01:32 |
| pubchem | ok | 2026-11-20 19:01:30 |
| missing (no r/tripreports posts mention it) | 2026-11-20 19:01:30 | |
| sider | ok | 2026-11-20 19:01:30 |
| structure | ok | 2026-11-20 19:01:30 |
| wikipedia | ok | 2026-11-20 19:01:30 |